

Suppl. Table S1: Clinical data of the complete study cohort vs. the WES cohort and the WES+RNA-Seq cohort.

Parameter	Category	Complete study cohort	WES cohort	P-value	WES + RNA-Seq cohort	P-value
Number of patients		174	149		136	
Age	< 40yr	47 (27.0%)	37 (24.8%)	0.144	33 (24.3%)	0.149
	≥ 40yr	127 (73.0%)	112 (75.2%)		103 (75.7%)	
Stage	0-I	61 (35.1%)	51 (34.2%)	0.652	47 (34.6%)	0.848
	IIA or higher	113 (64.9%)	98 (65.8%)		89 (65.4%)	
Histol. Grade	G2	29 (16.7%)	22 (14.8%)	0.142	21 (15.4%)	0.461
	G3	145 (83.3%)	127 (85.2%)		115 (84.6%)	
TILs	< 60%	149 (85.6%)	128 (85.9%)	0.762	116 (85.3%)	1.000
	≥ 60%	25 (14.4%)	21 (14.1%)		20 (14.7%)	
PD-L1	negative	20 (12.7%)	16 (12.0%)	0.526	14 (11.3%)	0.382
	positive	138 (87.3%)	117 (88.0%)		110 (88.7%)	
Treatment arm	Placebo	86 (49.4%)	75 (50.3%)	0.667	67 (49.3%)	1.000
	Durvalumab	88 (50.6%)	74 (49.7%)		69 (50.7%)	
Window treatment	No	57 (32.8%)	48 (32.2%)	0.818	47 (34.6%)	0.435
	Yes	117 (67.2%)	101 (67.8%)		89 (65.4%)	
Response	RD	89 (51.1%)	82 (55.0%)	0.017	72 (52.9%)	0.463
	pCR (ypT0ypN0)	85 (48.9%)	67 (45.0%)		64 (47.1%)	